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Abstract 
The objective of this cross-sectional study was to validate an abridged version of the 
Anosognosia Questionnaire - Dementia (AQ-D) for screening anosognosia in daily 
practice. The authors reduce the AQ-D from 30 items to 9, with a large sample of 
Alzheimer’s disease (AD) patients (n=352). The Cronbach’s alpha was 0.793 and an 
area under the COR curve was 0.946. Kappa index between new Abridged AQ-D 
(AAQ) and original AQ-D was =0.800. The AAQ presents good validity and reliability 
indicators and kept concordance with the original scale. It is quick and easy to 
administer and it can simplify the clinical screening of anosognosia in AD patients. 
 
KEYWORDS: Alzheimer disease [MeSH], Awareness [MeSH], Neuropsychological 
Tests [MeSH], Agnosia [MeSH], Dementia [MeSH], Cognitive Disorders [MeSH]  
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Introduction 
The construct of anosognosia in dementia is evolving very fast, and while some 
studies analyze the neurological and neuropsychological correlates of anosognosia in 
cognitive impairment, others use the latest neuroimaging technologies to identify 
structural or functional disruptions that may explain the lack of disease awareness in 
some patients with Alzheimer’s disease1-4. 
Consequences of anosognosia on both the patient and the caregiver are widely 
known. In 1914, Babinski5 described this disorder in post-stroke hemiplegic patients, 
and later on, it has been described in a variety of pathologies5-8. The prevalence of 
anosognosia ranges between 11 and 70% in Alzheimer’s disease, and has been 
associated with more severe cognitive impairment, although it can be seen in early 
stages too9-10. 
Anosognosia has also been associated with increased frequency and severity of 
behavioral and psychological symptoms of dementia, mainly with apathy, disinhibition, 
irritability, and delusions11-13. The main consequences of anosognosia are increased risk 
behaviors, lower treatment adherence, and increased difficulties for the family to 
manage the patient. In this sense, the presence of anosognosia has been associated with 
higher caregiver burden and increased institutionalization14-16. 
Given the significant impact of anosognosia on the patients and their environment, 
performing a systematic assessment in clinical practice would be advisable. However, 
there is a lack of quick and reliable tools to perform a screening, which would allow 
selecting those patients requiring further evaluation of anosognosia and its clinical 
consequences. Among the available tools to assess anosognosia, there are some brief 
classic subjective scales, such as the Experimenter Rating Scale or the Anosognosia 
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Rating Scale, but they require the physician to perform a wide exploration before a 
classification can be made17-18. Usually, the questionnaires for the assessment of 
anosognosia analyze the discrepancies detected between the patient’s and the 
caregiver’s reports9. Among these scales, the most commonly used, especially in 
research, is the Anosognosia Questionnaire – Dementia (AQ-D), because it includes a 
cognitive and functional assessment of the patient, and also takes into consideration 
changes in behavior19-20. Nevertheless, this questionnaire has 30 items, and its 
administration requires too much time to be used as a routine screening tool. 
Therefore, the aim of this study was to confirm that the abbreviated version of the 
AQ-D is a valid instrument to screen for the presence of anosognosia in concordance 
with the original questionnaire, which would provide a tool allowing a quick and 
reliable diagnosis of anosognosia in clinical practice. 
 
Methods 
Design: A cross-sectional, observational, and analytical study  
Patients 
The sample set comprised patients with mild, moderate, and severe AD who were 
diagnosed at two different memory clinics (Hospital Santa Caterina in Girona (HSC), 
Spain and Hospital Universitari de Bellvitge in Barcelona (HUB), Spain). Patients with 
probable AD according to the criteria outlined by the National Institute of Neurological 
and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders 
Association21 who had a close, reliable caregiver capable of answering the questions 
about their states, and who were not institutionalized, were included. The study protocol 
5 
 
 
was approved by the Institutional Review Board of each hospital and all the participants 
signed the informed consent form.  
Procedure and instruments 
In a single study visit, patients were assessed by a trained psychologist that scored 
the patients according to a scale (described below), administered questionnaires, and 
registered the clinical information from the clinical chart of each patient.  
The AQ-D is a questionnaire comprised of 30 Likert-type response items with four 
response options (never, sometimes, often, and always) with a score ranging from 0 to 
90 points. The presence of anosognosia is determined by a difference between the 
caregiver’s and the patient’s score greater than 32 points. The AQ-D has a high internal 
consistency (Cronbach alpha = 0.91) and a good inter-examiner reliability (Charlson 
comorbidity index = 0.90)20. The factor structure includes two factors, a cognitive-
functional factor and a behavioral factor, which explain 38.9% of the total variance19. 
The data on the sociodemographic characteristics (age, gender, scholarship, civil 
status, and place of residence) of patients and caregivers were collected in a 
standardized questionnaire. The clinical assessment of patients was carried out using the 
following 4 scales. The Mini-Mental State Examination (MMSE) is a screening test for 
cognitive impairment. It has a score range of 0 to 30, with a lower score indicating 
greater cognitive impairment22. The Disability Assessment in Dementia (DAD)23 is a 
specific functional disability assessment scale for patients with dementia that is 
administered to the caregiver. It is comprised of 40 dichotomous (yes/no) questions that 
assess the ability of the patient to execute 17 basic activities of daily living and 23 
instrumental activities. “Yes” is scored as one and “no” is scored as 0, giving a score 
range of 0 to 40 points. The Neuropsychiatric Inventory (NPI)24 is a validated method 
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for the assessment of the presence of behavioral and psychological symptoms of 
dementia (BPSD). It is filled out by the caregiver and consists of 12 subscales in which 
the frequency and severity of delusions, hallucinations, agitation, depression/dysphoria, 
anxiety, euphoria, apathy, disinhibition, irritability, motor disturbances, sleep disorders 
and eating disorders are assessed. The score is the product of the frequency (range = 1–
4) and the severity (range = 1–3) of the symptoms, with the total score ranging from 0 
to 144 points. The Global Deterioration Scale (GDS) 25, which ranges from 1 (no 
cognitive decline) to 7 (severe cognitive decline) assesses the stage of disease 
progression of the patient with dementia. The GDS-4 includes cases of mild dementia, 
the GDS-5 includes cases of moderate dementia, and the GDS-6 includes cases of 
moderate-severe dementia. 
Statistical analysis 
An extensive analysis of the results was performed by both absolute and relative 
frequencies for qualitative variables, or by central tendency and dispersion 
measurements for quantitative variables. 
New variables were created from the difference between the caregiver’s and 
patient’s score in each of the 30 Likert-type response items. From these new variables, 
we carried out an exploratory factor analysis (EFA) with Promax rotation (which allows 
for correlation between the factors) and constraining the resulting factor structure to two 
factors, to maintain the structure of the original scale18. We constructed the abridged 
questionnaire by selecting the variables with an absolute difference in the eigenvalues 
of the two factors ≥0.6026. 
The internal consistency of the abridged questionnaire was evaluated using the 
Cronbach alpha coefficient. The level for acceptable reliability was an alpha coefficient 
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≥0.7. A new EFA of the abbreviated questionnaire was carried out to compare the factor 
structure with the original AQ-D factor structure. To determine the cut-off points for the 
abridged questionnaire, ROC curves were used. The area under the curve (AUC), as 
well as the sensitivity and specificity of each cut-off point, were determined for all 
adjusted ROC curves. The optimal cut-off point was established based on the maximum 
sum of sensitivity and specificity.  
We compared the validity of the criteria for the AQ-D and the Abridged 
Anosognosia Questionnaire (AAQ) by calculating the kappa index. The convergent 
validity and discriminant validity were assessed by calculating the Pearson or 
Spearman’s correlation coefficient with the MMSE, DAD and NPI scales for the overall 
score of the abridged questionnaire and the score of each factor.  
The results are expressed as absolute numbers, percentages, averages, standard 
deviations, and 95% confidence intervals (CIs). The level of statistical significance was 
set at 0.05 to test hypotheses. All data processing and analysis was performed using 
SPSS version 17.0 for Windows.  
 
Results 
We studied a sample of 352 patients with AD, 69% of which were women, with a mean 
age of 79.2 years (SD = 6.6), of which 53.5% of the cases had a level of education 
below basic studies, 36.4% had primary studies, and 9.9% had middle or higher studies. 
The mean age of the primary caregivers was of 61.4 years (SD = 13.7). Most were 
women (69.3%), and 43.8% of the caregivers were the patients’ spouses and the rest 
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were the children (51.0%) or other relatives (5.2%). The clinical and sociodemographic 
data of the sample are described in Table 1.  
The mean score in the AQ-D was 29.4 points (SD = 20.3; range= -19.0–88.0). The 
prevalence of anosognosia according the AQ-D score (discrepancy ≥32 points) was 
45.7% (95% CI = 41.0–52.5).  
The FA applied to the AQ-D explained 56.2% of the variance. There were nine 
items with an eigenvalue difference ≥0.60 between two factors and these items were 
selected as representative questions from the abbreviated AQ-D scale (Table 2). The 
wording of each of the nine items of the new AAQ is also in Table 2. 
The EFA applied to the AAQ also grouped the items into two factors, explaining 
57.9% of the variance, and maintaining the factor structure of the original AQ-D. The 
internal consistency of the AAQ was within acceptable limits (Cronbach alpha = 0.793). 
For the first factor, the Cronbach alpha was 0.815 and the second factor was 0.627, with 
an AUC of 0.946. The presence of anosognosia was established when there was a 
difference of ≥13 points between the caregiver’s and patient’s responses, with a 
sensitivity and specificity that when compared to the original scale was above 0.8 
(0.909 and 0.859, respectively).  
The prevalence of anosognosia diagnosis with the AAQ was 47.2% (95% CI = 
41.8–52.5). When compared side-by-side with the AQ-D, the validity of the criteria for 
the AAQ was acceptable, with a kappa index = 0.800 (CI 95% = 0.737–0.863). Figure 1 
shows the ROC curve for the AAQ (AUC = 0.946). Since samples from two different 
sites were available, a comparative study was carried out separately using the data from 
each site. The results showed agreement for both HSC and HUB, kappa = 0.800 and 
kappa = 0.776, respectively. The analysis of the construct discriminant validity of the 
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factors showed an inverse correlation between MMSE scores and the first factor 
(cognitive and functional) in both patients with anosognosia (Spearman’s rho = -0.215; 
p = 0.015) and without (Spearman’s rho = -0.194; p = 0.008). Similar results were 
obtained between the DAD scale and the first factor for patients with (Spearman’s rho= 
-0.314; p <0.001) and without (Spearman’s rho = -0.184; p = 0.012) anosognosia. A 
direct correlation was detected between the second factor (behavioral) and the NPI 
scores in patients with and without anosognosia (Spearman’s rho = 0.445; p <0.001 and 
Spearman’s rho = 0.198; p = 0.007, respectively), and it was stronger in the former. In 
the analysis of the construct discriminant validity, the AAQ score showed significant 
differences in each of the stages of the GDS (F = 34.6; gl = 2; p <0.001). Spearman’s 
correlation coefficients were moderate to high with the NPI scale (rho = 0.573; p 
<0.001) and the DAD scale (rho = -0.333; p <0.001) and, to a lesser extent, with the 
MMSE (rho = -0.167; p= 0.002). Regarding sociodemographic characteristics, the 
previously detected differences using the original scale were still observed, thus, cases 
with anosognosia were older (U Mann Whitney = 12,313.0; p=0,008), but no 
differences in the gender, civil status and education were detected (gender: 2=0,012; 
gl=1; p=0,934. Civil status: 2=2,129; gl=3; p=0,345. Education: 2=0,911; gl=2; 
p=0,637). Regarding the residence of the caregivers, as when evaluated with AQ-D, 
sons lived more frequently with the patients with anosognosia (2=11,5; gl=1; p=0,001).  
 
Discussion 
Anosognosia is frequently diagnosed in those suffering from AD. Despite this, it is 
poorly studied in daily clinical practice, mainly due to the lack of defined diagnostic 
criteria. Specifically, there is disagreement on whether to consider anosognosia a focal 
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or global disorder, as well as there being a discrepancy between the dimensional and 
dichotomic (presence/absence) assessments27-29. These aspects are directly associated 
with the use of different methodologies and instruments for assessment30-31.  
The selection of the AQ-D for the study of anosognosia was carried out based on 
the fact that it discriminates between patients with minimal alterations of awareness of 
the disease and patients who clearly present with anosognosia. Also, the AQ-D is a 
scale that was developed for detecting anosognosia globally19, incorporating the 
assessment of cognitive disorders, as well as functional and behavioral disorders18. 
Despite its use by different research groups32-33, the use of the AQ-D in the context of 
clinical practice is not common and the clinical diagnosis of anosognosia continues to 
be through clinical anamnesis. One reason is that there is a lack of a gold standard test 
that allows for definite distinction between patients with and without anosognosia. 
Another limiting factor is the lack of a test that is easy to use and quick to administer. 
The AAQ satisfies these requirements and provides a more comprehensive and 
standardized way to assess anosognosia.  
The results reported here have shown that the AAQ is equivalent to the original 
scale and that it identifies the presence of anosognosia in patients with AD accurately. 
We note that the items selected in the AAQ correctly evaluate memory loss, an aspect 
that is frequently assessed in different scales for evaluating cognitive impairment in AD 
patients. Remembering events or remembering the shopping list and the ability to use 
currency are items of the cognitive assessment (part A) of the Blessed Dementia Rating 
Scale (BDRS) 34, one of the scales most used in the diagnosis and follow-up of AD. The 
items remembering telephone calls and ability to carry out transactions are included in 
the functional evaluation scale of the Disability Assessment in Dementia23, which is 
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widely used in studies and clinical trials. Likewise, the items being more self-seeking 
and being more irritable are items that are a part of section C (behavioral subscale) of 
the BDRS.  
The frequency and severity of the BPSD is high in patients with anosognosia. The 
AAQ correlates well with the presence of BPSD as previous studies have indicated, 
showing a high association with frontally mediated disorders11, 12. The 33.8% of the 
study patients who were in a mild or initial phase of disease stage were found to have a 
strong correlation between anosognosia and behavioral disorders including irritability, 
apathy and disinhibition, disorders associated with the alteration of the abilities of 
planning and organizing34. This aspect is important, as the presence of dysexecutive 
disorders in the initial phases of anosognosia may lead to a greater exposure of the 
patients to higher risk behaviors and making poor decisions that may affect the patients 
themselves as well as the people around them2, 14. This highlights the importance of 
studying anosognosia in daily clinical practice, both for adjusting the pharmacological 
and non-pharmacological treatments, as well as avoiding risky situations and adjusting 
strategies of psychoeducational support to relatives. 
Scale abbreviation, which is typically done for scales that are used frequently, is a 
common technique that is done to facilitate the care and supervision of patients in 
clinical practice. Currently, there are condensed versions of scales as common as the 
Neuropsychiatric Inventory, the Geriatric Depression Scale, and the Burden Interview, 
among others34-38, which has made it easier to include them in research protocols, 
during clinical care, and during socio-sanitary care. In addition to the AAQ being in 
agreement with the original scale, it has excellent sensitivity and specificity rates. The 
new AAQ scale preserves the structure of two factors with the items, the first of which 
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is associated with cognitive and functional abilities, and the second is related to 
behaviour. Moreover, the correlations existing between the first factor (cognitive and 
functional) and the MMSE score, and between the second factor (behaviour) and the 
NPI score, not only increase the discriminating validity of the factors, but also support 
the decision to force the result of the first FA. It should be noted that while the cut-off 
point selected in the AAQ has high values of sensitivity and specificity compared to the 
original scale, it also has a greater sensitivity than the AQ-D, a feature that should be 
taken into account during the study of anosognosia.  
One limitation in this AAQ validation study is that the sample set was not 
specifically selected for this purpose. However the inclusion of AD patients in different 
stages of disease progression was taken into account (as was the case in the original 
factor structure validation study). Another limitation was in the determination of the 
items of the AAQ, as there are multiple forms for this purpose. In this study, we 
prioritized the factor structure of the original scale presented with a composition of two 
factors. However, the indexes of concordance with the original scale demonstrate that 
the items selected are adequate and the factor structure has been maintained. 
Importantly the number of items is sufficiently reduced to render the abbreviated scale 
more practical than the original scale. In addition, the two items comprising the two 
factor scale refer to aspects easily observed clinically in dementia patients.  
Currently, pressure on health care services makes it difficult to expand the study of 
patients, and the use of psychometric instruments is being reduced to the essential 
minimums. The incorporation and use of new scales is directly correlated to the time of 
administration and to the information it provides39. Under these circumstances, for the 
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study of anosognosia, the use of the AAQ is advisable, as it allows a valid and reliable 
diagnosis to be reached more swiftly. 
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NOTE: *The scholarship of the patient could not be established in one case.GDS = Global  
Deterioration Scale; MMSE = Mini-Mental State Examination; DAD = Disability 
Assessment in Dementia; NPI = Neuropsychiatric Inventory. 
 
 
 
Table 1. Clinical and sociodemographic characteristics of patients. 
 TOTAL 
 
N= 352  
Age, mean (SD) 79.2 (6.6) 
Gender –female-, n (%) 98 (69.0) 
Civil status, n (%)  
Married 226 (64.2) 
Widow/widower 117 (33.2) 
Other 9 (2.6) 
Education*, n (%)  
Illiterate 32 (9.1) 
Low  156 (44.4) 
Elementary 128 (36.4) 
High 35 (9.9) 
Place of residence, n (%)  
Private 292 (83.0) 
Relative 55 (15.6) 
Institution 5 (1.4) 
GDS, n (%)  
4-mild 196 (55.7) 
5-moderate 123 (34.9) 
6-severe 33 (09.4) 
MMSE, mean (SD) 17.7 (5.1) 
DAD, mean (SD) 60.9 (11.1) 
NPI, mean (SD) 21.5 (19.6) 
Delusions 1.2 (2.7) 
Hallucinations 0.4 (1.6) 
Agitation 1.7 (0.2) 
Depression 2.2 (3.1) 
Anxiety 1.9 (3.2) 
Euphoria 0.5 (1.5) 
Apathy 4.5 (4.3) 
Disinhibition 1.2 (2.5) 
Irritability 2.8 (3.6) 
Behavioral disturbances 1.6 (3.3) 
Sleep disorders 1.1 (2.7) 
Eating disorder 2.3 (4.8) 
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Table 2. Matrix of the results of the analysis of main components with Promax rotation 
and Kaiser normalization. 
ITEMS F1 F 2 Dif* 
1. Do you have problems remembering the date? 0.696 -0.147 0.5 
2. Do you have problems orienting yourself in new places? 0.694 -0.157 0.5 
3. Do you have problems remembering telephone calls? 0.823 -0.132 0.7 
4. Do you have problems understanding conversations? 0.235 0.518 -0.3 
5. Do you have problems signing your signature? 0.287 0.270 0.0 
6. Do you have problems understanding what you read in 
the newspaper? 
 
0.478 0.247 0.2 
7. Do you have problems keeping your personal belongings 
in order? 
 
0.555 0.076 0.5 
8. Do you have problems remembering where you leave 
things in your home? 
 
0.736 -0.046 0.7 
9. Do you have problems writing notes or letters? 0.530 0.161 0.4 
10. Do you have problems to use handling money? 0.740 -0.040 0.7 
11. Do you have problems orienting yourself in your 
neighborhood? 
 
0.486 0.171 0.3 
12. Do you have problems remembering appointments? 0.767 -0.156 0.6 
13. Do you have problems practicing your favorite hobbies? 0.573 0.189 0.4 
14. Do you have problems communicating with people? 0.204 0.522 -0.3 
15. Do you have problems doing mental calculations? 0.408 0.241 0.2 
16. Do you have problems remembering things you have to 
buy when you go shopping? 
 
0.858 -0.199 0.7 
17. Do you have problems controlling your sphincters? 0.057 0.392 -0.3 
18. Do you have problems understanding the plot of a 0.566 0.158 0.4 
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movie? 
 
19. Do you have problems orienting in your house? 0.139 0.315 -0.2 
20. Do you have problems doing home activities (cooking, 
cleaning, fixing things, etc.)? 
 
0.681 0.072 0.6 
21. Do you have problems feeding yourself? -0.006 0.489 -0.5 
22. Do you have problems keeping your checkbook, 
accounts, payments, etc.? 
 
0.683 -0.075 0.6 
23. Are you more rigid in your decisions, with less capacity 
to adapt to new situations? 
 
0.106 0.584 -0.5 
24. Are you more egotistic, paying less attention to other 
people’s needs? 
 
-0.081 0.690 -0.6 
25. Are you more irritated? Do you easily lose your temper? 0.023 0.681 -0.6 
26. Do you have crying episodes? -0.152 0.409 -0.3 
27. Do you laugh in inappropriate situations? -0.134 0.551 -0.4 
28. Are you more interested in sexual themes, talking or 
reading about sex? 
 
-0.286 0.577 -0.3 
29. Have you lost interest in hobbies or activities you used to 
like? 
 
0.363 0.276 0.1 
30. Do you feel more depressed? 0.129 0.227 -0.1 
*Dif. = difference in absolute values.  
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Figure 1. Graphical representation of the area under ROC curve for the AAQ. 
 
 
